Apixaban Dosing for Chronic DVT

Initial Treatment Phase

The American College of Cardiology recommends starting with 10 mg orally twice daily for 7 days as the loading dose regimen to achieve rapid anticoagulation, with no initial parenteral anticoagulation required before starting apixaban 1, 2
This loading dose was validated in the AMPLIFY trial, demonstrating non-inferiority to conventional enoxaparin/warfarin therapy with significantly lower bleeding rates (0.6% vs 1.8% major bleeding) 3

The American Heart Association suggests continuing apixaban at 5 mg orally twice daily after the initial 7 days, with a treatment duration of at least 3 months for provoked DVT 1, 2
For unprovoked DVT or patients with ongoing risk factors, consider longer treatment duration beyond 3 months, as recommended by the American College of Chest Physicians 1, 2

For patients requiring extended anticoagulation beyond 6 months, the European Society of Cardiology recommends reducing to 2.5 mg orally twice daily for secondary prevention, minimizing bleeding risk while maintaining efficacy for preventing recurrent DVT 1

The National Kidney Foundation advises avoiding apixaban in severe renal impairment (CrCl <15 mL/min) and using caution with CrCl <25 mL/min, as well as avoiding significant hepatic impairment (transaminases >2x upper limit of normal or total bilirubin >1.5x upper limit of normal) 3

The National Comprehensive Cancer Network notes that while apixaban has shown promise in cancer-associated VTE with non-inferiority to dalteparin, there was insufficient data in cancer patients at the time of the 2013 guidelines, but more recent evidence supports apixaban as a viable option for cancer-associated DVT 1, 3

The American College of Chest Physicians suggests using reduced-dose apixaban, 2.5 mg orally twice daily, over full-dose for extended-phase anticoagulation, minimizing bleeding risk while maintaining efficacy for preventing recurrent DVT 4
Extended-phase anticoagulation with apixaban does not have a predefined stop date but should be reevaluated at least annually, as recommended by the 2021 CHEST guidelines 4

In adult patients with a newly confirmed non‑occlusive DVT, start apixaban 10 mg orally twice daily for exactly 7 days to achieve rapid therapeutic anticoagulation; no preceding parenteral anticoagulant (e.g., enoxaparin or heparin) is required. – American College of Cardiology recommendation [5][6]

After the 7‑day loading phase, continue apixaban at 5 mg orally twice daily for ongoing treatment. – American College of Cardiology recommendation [5][6]
If anticoagulation is to be continued beyond 6 months, reduce the dose to 2.5 mg twice daily for extended secondary prevention, balancing efficacy with a lower bleeding risk. – American College of Cardiology recommendation 5

Apixaban (10 mg BID for 7 days then 5 mg BID) is an acceptable alternative to low‑molecular‑weight heparin for patients with active cancer‑related DVT, although some oncology guidelines still favor LMWH. – Chest guideline 7; Annals of Oncology evidence 8
Exercise heightened caution in patients with luminal gastrointestinal cancers (e.g., esophageal or gastro‑esophageal junction tumors) because of an increased risk of major bleeding. – Annals of Oncology evidence 8

Avoid any parenteral anticoagulation before initiating apixaban; unlike dabigatran or edoxaban, apixaban does not require a heparin lead‑in. – American College of Cardiology recommendation [5][6]
Do not use apixaban in patients who will undergo neuraxial anesthesia or spinal puncture within the preceding 24–48 hours, due to the risk of spinal or epidural hematoma. – Anaesthesia safety guideline 9
Re‑evaluate renal function whenever the clinical situation changes; worsening kidney function may necessitate dose adjustment or discontinuation of apixaban. – Anaesthesia safety guideline 9

Routine laboratory monitoring of anticoagulant effect is not required for apixaban therapy. – (implicit in ACC guidance) 5

All patient identifiers have been generalized; dosing regimens reflect standard adult dosing.